CAPLIPOINT - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 3.6
| Stock Code | CAPLIPOINT | Market Cap | 19,049 Cr. | Current Price | 2,506 ₹ | High / Low | 2,560 ₹ |
| Stock P/E | 48.0 | Book Value | 270 ₹ | Dividend Yield | 0.24 % | ROCE | 27.0 % |
| ROE | 21.1 % | Face Value | 2.00 ₹ | DMA 50 | 2,027 ₹ | DMA 200 | 1,912 ₹ |
| Chg in FII Hold | -0.43 % | Chg in DII Hold | 0.09 % | PAT Qtr | 110 Cr. | PAT Prev Qtr | 87.3 Cr. |
| RSI | 79.1 | MACD | 138 | Volume | 4,36,937 | Avg Vol 1Wk | 1,69,610 |
| Low price | 1,500 ₹ | High price | 2,560 ₹ | PEG Ratio | 2.48 | Debt to equity | 0.00 |
| 52w Index | 94.9 % | Qtr Profit Var | 26.6 % | EPS | 52.2 ₹ | Industry PE | 32.5 |
CAPLIPOINT shows limited potential for swing trading at the current levels. The stock is trading at ₹2,506, very close to its 52-week high of ₹2,560, which suggests overbought conditions. RSI at 79.1 confirms strong momentum but also signals caution as it is in the overbought zone. MACD at 138 indicates bullish strength, yet the high P/E of 48 compared to industry P/E of 32.5 and PEG ratio of 2.48 highlight expensive valuations. On the positive side, the company has zero debt and strong profitability metrics (ROCE 27%, ROE 21.1%).
✅ Optimal Entry Price: ₹2,300–₹2,350 (closer to 50 DMA support)
📈 Exit Strategy (if already holding): Consider booking profits near ₹2,550–₹2,560 unless momentum breaks out strongly above resistance.
🌟 Positive
- 📈 Strong quarterly PAT growth (₹87.3 Cr. → ₹110 Cr., up 26.6%).
- 💹 Excellent ROCE (27%) and ROE (21.1%) indicate efficient capital use.
- 📊 EPS of ₹52.2 shows solid earnings power.
- 💳 Debt-to-equity ratio of 0.00 reflects a debt-free balance sheet.
⚠️ Limitation
- 📉 Very high P/E of 48 compared to industry average of 32.5.
- 📊 PEG ratio of 2.48 suggests overvaluation relative to growth.
- 💸 Dividend yield of 0.24% is negligible.
- 📈 RSI at 79.1 indicates overbought conditions.
📰 Company Negative News
- 📉 Decline in FII holding (-0.43%) shows reduced foreign investor confidence.
📰 Company Positive News
- 📈 Increase in DII holding (+0.09%) signals domestic institutional support.
- 💹 Strong quarterly PAT growth supports bullish sentiment.
🏭 Industry
- 📊 Industry P/E at 32.5 is lower than CAPLIPOINT’s 48, suggesting overvaluation.
- 🏥 Pharma sector remains resilient with consistent demand and growth opportunities.
✅ Conclusion
CAPLIPOINT is fundamentally strong with debt-free status and high profitability, but valuations are stretched and technical indicators show overbought conditions. Entry around ₹2,300–₹2,350 is safer, while profit booking near ₹2,550–₹2,560 is advisable if already holding. Caution is warranted due to expensive valuations and limited upside in the near term.
Would you like me to also contrast CAPLIPOINT’s swing trade outlook with another pharma stock like Divi’s Lab or Sun Pharma to highlight relative opportunities?